Enfortumab vedotin for advanced small bowel adenocarcinoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a drug called enfortumab vedotin for people with advanced small bowel adenocarcinoma that has worsened after platinum-based chemotherapy. The goal is to see if it can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of small bowel adenocarcinoma that is advanced or has come back after surgery.
- Your cancer must have gotten worse, come back, or you had to stop treatment due to side effects after receiving platinum-based chemotherapy like FOLFOX or CapeOX.
- You need to be at least 18 years old and in generally good health, able to care for yourself (ECOG score 0 or 1).
- You must have at least one tumor that can be measured on a CT scan.
- You must not have active infections, uncontrolled diabetes, or serious heart or lung problems.
- You must agree to provide a tumor sample (from a previous biopsy or a new one) and use effective contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug, sacituzumab tirumotecan, for people with advanced small bowel adenocarcinoma that has not responded to or cannot tolerate platinum-based chemotherapy. The drug targets a protein called TROP2 on cancer cells to deliver treatment directly to them.
This trial tests a drug called enfortumab vedotin for people whose colorectal or liver cancer has spread or cannot be removed and has stopped responding to or is intolerant to standard treatments. The drug is given through a vein and works by targeting cancer cells.
This trial tests a drug called enfortumab vedotin for people with adenoid cystic carcinoma (ACC) that has spread or come back. The drug is given through a vein and may help shrink tumors or slow the cancer.
This trial tests a drug called enfortumab vedotin for people with advanced penile cancer (squamous cell carcinoma) that has spread or cannot be surgically removed. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
This study tests a new drug called enfortumab vedotin for people whose advanced urothelial cancer (bladder or urinary tract cancer) has not responded to prior immunotherapy (checkpoint inhibitors) and platinum chemotherapy. The goal is to see how safe and effective this treatment is for Indian adults.
This trial tests a combination of a targeted drug (enfortumab vedotin) and focused radiation before surgery to remove the bladder. It is for people with muscle-invasive bladder cancer who cannot take cisplatin chemotherapy.
Hear when a new Advanced Small Bowel Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.